drugset / Trial / NCT02007512

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

NCT02007512

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if enzalutamide given in combination with exemestane is safe and effective in patients with advanced breast cancer.

Timeline

Start
2013-12-16
Primary completion
2016-09-23
Completion
2024-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Enzalutamide Other / unclassified 160 mg Oral
Subject Exemestane Small molecule 25 mg Oral
Subject Exemestane Small molecule 50 mg Oral

Indications